Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease

Exclusion Criteria

• •1. In the judgment of the investigator the patient is not a good candidate for the study;
• •2. Blood transfusion with in the last 90 days from date of Screening;
• •3. Symptoms or electrocardiogram (ECG)-based signs of acute myocardial infarction, Unstable angina pectoris, decompensated heart failure, third degree heart block or cardiac arrhythmia associated with hemodynamic instability;
• •4. Total bilirubin greater than 1.5 mg/dL or transaminase (ALT, AST) elevations greater than 2 times the upper limit of the laboratory reference range or evidence of significant hepatic insufficiency;
• •5. Concurrent or prior treatment within 90 days of Screening with an investigational medication;
• •6. Chronic treatment (as determined by the Investigator) with any immunosuppressive medication (including corticosteroids) within the past 90 days of Screening;
• •7. Evidence or history of regular alcohol abuse;
• •8. Screening laboratory result(s) determined to be clinically significant by the investigator;
• •9. Screening laboratory result indicating HIV-positivity, or previously diagnosed with AIDS, AIDS related complex or any other immunodeficiency;
• •10. Screening laboratory result or laboratory results performed within one year indicating positivity for hepatitis B surface antigens, hepatitis B core antibodies, or hepatitis C antibodies;
• •11. Uncontrolled Diabetes Mellitus (Patients with HbA1c \> 9% at screening)